Skip to main content

Hypotensive peptides from milk proteins

Objective

Milk protein peptides can inhibit angiotensin-I-converting enzyme (ACE) Drugs, which inhibit ACE, are in widespread use in cardiovascular medicine. Little or no information is available on the physiological efficacy in man of ingesting natural milk protein peptides/hydrolysis's, which inhibit ACE in vitro. Therefore, it is proposed to address this European-wide functional food ingredient problem/opportunity. The proposal objectives are to perform a detailed physiological, physicochemical, immunochemical and catechetical characterisation, in addition to a consumer assessment of these naturally derived inhibitors of ACE. Milk proteins will be hydrolysed using food-grade proteases. Clinical/bio availability trials will be performed in human volunteers. Immunochemical studies will use serum samples from humans fed ACE inhibitory hydrolysis. Catechetical studies will use human cell culture systems. Consumer awareness will be assessed on a global basis. The outcome of this proposal should lead to the development of clinically validated health claims in respect to the physiological efficiency and safety of ingesting milk protein-derived inhibitors of ACE.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY OF LIMERICK
Address
Plassey Technological Park
61 Limerick
Ireland

Participants (3)

FEDERAL RESEARCH CENTRE FOR NUTRITION AND FOOD
Germany
Address
Hermann Weigmann Straße 1
24103 Kiel
GLANBIA INGREDIENTS (BALLYRAGGET) LTD
Ireland
Address
Ballyragget
Co. Kilkenny
UNIVERSITY OF DUNDEE
United Kingdom
Address
Ninewells Hospital And Medical School
DD1 9SY Dundee